Dilated cardiomyopathy (DCM) is not the same thing as heart failure, but it is one of the most common causes of it. DCM is a structural problem: the heart’s main pumping chamber stretches and weakens. Heart failure is the clinical result: the heart can no longer pump enough blood to meet the body’s needs. Most people with DCM will eventually develop heart failure symptoms, but heart failure itself can also be caused by coronary artery disease, valve problems, high blood pressure, and other conditions that have nothing to do with cardiomyopathy.
Understanding the distinction matters because treatment depends partly on identifying the underlying disease. A doctor managing heart failure needs to know whether the weak pump is caused by DCM, blocked coronary arteries, or something else entirely.
How DCM Changes the Heart
In a healthy heart, the left ventricle is a thick-walled, muscular chamber that contracts forcefully with each beat. In DCM, that chamber gradually enlarges and its walls thin out. Think of it like a balloon that has been overinflated too many times: the walls stretch, lose their elasticity, and can no longer squeeze with the same strength.
This weakening shows up on imaging as a reduced ejection fraction, which measures the percentage of blood the left ventricle pushes out with each beat. A normal ejection fraction is roughly 55% to 70%. DCM is typically diagnosed when the ejection fraction drops below 40% and the ventricle is visibly enlarged on an echocardiogram or other imaging. As the chamber stretches further, the heart compensates by beating faster and retaining fluid, but these adaptations eventually make things worse, creating the cycle that leads to heart failure symptoms.
What Causes Dilated Cardiomyopathy
DCM has both genetic and acquired causes. A genetic basis is found in roughly 25% to 35% of cases. Mutations in more than 20 genes have been linked to the condition, with variants in a single gene called TTN accounting for about 15% to 20% of all DCM cases. Certain gene mutations (in LMNA, FLNC, RBM20, DSP, and PLN) carry a notably higher risk of dangerous heart rhythm problems, which influences how aggressively doctors monitor and treat those patients.
Acquired causes include viral infections that damage heart muscle, long-term heavy alcohol use, certain chemotherapy drugs, damage from a prior heart attack, and severe valve disease. In many cases, no clear cause is ever identified. When coronary arteries are unobstructed and no other explanation is found, a diagnosis of idiopathic DCM is made.
Symptoms and How They Progress
Many people with DCM have no symptoms in the early stages. The heart compensates well enough that daily life feels normal, and the condition is sometimes discovered incidentally during imaging done for another reason.
As the heart weakens further, the hallmark symptoms of heart failure emerge. Shortness of breath during physical activity is usually the first sign. Over time, breathing can become difficult even while lying flat, forcing some people to prop themselves up on pillows to sleep. Fluid retention leads to swelling in the legs, ankles, feet, or abdomen. Fatigue that seems out of proportion to your activity level is common, because less blood is reaching your muscles and organs with each heartbeat. Some people notice a rapid or irregular heartbeat, dizziness, or a persistent cough.
The timeline varies enormously. Some people remain stable for years with medication. Others progress more quickly, particularly if the underlying cause is aggressive or if the condition goes undiagnosed and untreated for a long time.
Serious Risks: Arrhythmias and Sudden Death
One of the most concerning aspects of DCM is the risk of dangerous heart rhythms. The stretched, scarred heart muscle can generate abnormal electrical signals that trigger ventricular arrhythmias, where the lower chambers of the heart quiver instead of pumping. An estimated 30% of deaths among patients with DCM and an ejection fraction below 35% are caused by these arrhythmias rather than by the gradual worsening of pump function.
Ejection fraction alone is an imperfect predictor of who will have a life-threatening rhythm problem. Genetic testing is increasingly important because specific mutations carry much higher arrhythmia risk, and that information can change whether a device like an implantable defibrillator is recommended.
How DCM-Related Heart Failure Is Treated
Treatment focuses on two goals: improving the heart’s pumping ability and preventing the condition from getting worse. The medications that have most improved survival are blood pressure drugs that reduce the workload on the heart (ACE inhibitors or related medications) and beta-blockers that slow the heart rate and allow the chambers to fill more completely. Most people with DCM-related heart failure take both, along with other drugs that help the body clear excess fluid or protect the heart from further remodeling.
These medications can produce real improvement. Some people see their ejection fraction climb significantly over the first three to six months of treatment, and a meaningful number recover enough heart function that their symptoms stabilize or even partially resolve.
Implantable Defibrillators
For people whose ejection fraction remains at or below 35% despite optimal medication, guidelines recommend considering an implantable cardioverter-defibrillator (ICD). This small device, placed under the skin near the collarbone, continuously monitors heart rhythm and delivers a corrective shock if a life-threatening arrhythmia occurs. Current guidelines advise waiting at least three months after the initial DCM diagnosis before implanting one, because some hearts recover enough on medication that the device becomes unnecessary. If recovery seems unlikely, implantation is generally considered between three and nine months after diagnosis.
Advanced Options for Severe Cases
When heart failure progresses despite medications and device therapy, the options narrow to mechanical support or transplantation. A left ventricular assist device (LVAD) is a surgically implanted pump that helps the weakened ventricle move blood through the body. It can serve as a bridge while waiting for a heart transplant, or as a long-term solution for people who are not transplant candidates. Heart transplantation remains the most definitive treatment for end-stage DCM, though the limited supply of donor organs means it is reserved for the most severe cases.
Living With DCM
A DCM diagnosis does not automatically mean rapid decline. With early detection and consistent treatment, many people live for years with a good quality of life. The key factors that influence outcomes are how early treatment begins, whether the underlying cause is identifiable and treatable (such as stopping alcohol use or addressing a thyroid problem), and how well the heart responds to medication in the first several months.
Regular follow-up with imaging to track ejection fraction and chamber size helps your care team adjust treatment over time. Genetic testing and family screening are recommended when a hereditary cause is suspected, since first-degree relatives may carry the same mutation and benefit from early monitoring before symptoms appear.